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The adenosine diphosphate (ADP) receptor P2RY12 (purinergic receptor P2Y, G protein coupled, 12) plays a 
critical role in platelet aggregation, and P2RY12 inhibitors are used clinically to prevent cardiac and cerebral 
thrombotic events. Extracellular ADP has also been shown to increase osteoclast (OC) activity, but the role of 
P2RY12 in OC biology is unknown. Here, we examined the role of mouse P2RY12 in OC function. Mice lacking 
P2ry12 had decreased OC activity and were partially protected from age-associated bone loss. P2ry12–/– OCs 
exhibited intact differentiation markers, but diminished resorptive function. Extracellular ADP enhanced 
OC adhesion and resorptive activity of WT, but not P2ry12–/–, OCs. In platelets, ADP stimulation of P2RY12 
resulted in GTPase Ras-related protein (RAP1) activation and subsequent αIIbβ3 integrin activation. Likewise, 
we found that ADP stimulation induced RAP1 activation in WT and integrin β3 gene knockout (Itgb3–/–) OCs, 
but its effects were substantially blunted in P2ry12–/– OCs. In vivo, P2ry12–/– mice were partially protected from 
pathologic bone loss associated with serum transfer arthritis, tumor growth in bone, and ovariectomy-induced 
osteoporosis: all conditions associated with increased extracellular ADP. Finally, mice treated with the clinical 
inhibitor of P2RY12, clopidogrel, were protected from pathologic osteolysis. These results demonstrate that 
P2RY12 is the primary ADP receptor in OCs and suggest that P2RY12 inhibition is a potential therapeutic 
target for pathologic bone loss.
Introduction
Osteoclasts (OCs) are multinucleated myeloid lineage cells that are the 
principal source of bone resorptive activity (1). Enhanced OC activ-
ity, bone loss, and fractures are associated with rheumatoid arthri-
tis, postmenopausal osteoporosis, and bone metastases (2). Modu-
lation of osteoclastic bone resorption represents an attractive point 
of therapeutic intervention for the treatment of such conditions.
Numerous purinergic G-protein–coupled nucleotide receptors 
are expressed in the bone microenvironment (3, 4). For example, 
uridine diphosphate–activated (UDP-activated) P2Y6 has been 
reported to increase NF-κB activation and OC survival (5), while 
P2Y2 (an ATP receptor) expression on osteoblasts (OBs) blocks 
bone mineralization (6, 7). Hoebertz et al. demonstrated that 
extracellular adenosine diphosphate (ADP) stimulates OC bone 
resorption in vitro, in part through the ADP receptor P2Y1 on OC 
(8); however, other ADP receptors, including purinergic receptor 
P2Y, G protein coupled, 12 (P2RY12), which is the target of the 
widely prescribed antiplatelet drug clopidogrel (Plavix), have not 
been evaluated for their roles in osteoclastic bone resorption.
P2RY12, initially identified as the Gαi-coupled ADP receptor on 
platelets (9), plays a critical role in thrombus stability in vivo (10). 
The active metabolite of clopidogrel directly binds and irrevers-
ibly inhibits P2RY12 signaling, resulting in diminished platelet 
activation and aggregation, due in large part to reduced inside-
out activation of the critical platelet integrin αIIbβ3 (11). Mice with 
targeted disruption of the P2ry12 gene (P2ry12–/–) have prolonged 
bleeding times associated with a decrease in platelet function (9, 
10). P2RY12 signaling via Gαi results in Ras-related protein (RAP1) 
GTPase-mediated activation of αIIbβ3, which is required for plate-
let activation and aggregation (9, 12–17). RAP1 GTPase-mediated 
activation of β3-containing integrins has been shown to be nec-
essary for cell adhesion, spreading, and migration (13, 18–20). 
Importantly, β3 integrins also play critical roles in OC formation, 
adhesion, and bone resorption (21). We hypothesized that ADP 
ligation of P2RY12 would affect OC function in part through acti-
vation of αvβ3 integrin (22–25).
P2RY12 has been shown to be biologically important in microg-
lial cells, vascular smooth muscle cells, and brain endothelial 
cells (26–28) as well as in the growth of tumor cell lines (29, 30). 
P2RY12 is not expressed in splenic macrophages or in human alve-
olar macrophages and is expressed at negligible or very low levels 
in most other tissues (9, 31–33). Extracellular nucleotides such as 
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ADP/ATP are released during tissue injury, inflammation, tumor 
growth, and aging (34–38). ADP released during neuronal injury 
induces the P2RY12-dependent chemotaxis of microglia to the 
injury site, allowing for neuroprotective activity (31, 39, 40). We 
sought to examine the role of P2RY12 within the bone microenvi-
ronment during pathologic conditions associated with increases 
in extracellular ADP/ATP (36, 41–43).
We found that P2ry12–/– mice exhibited decreased OC activity 
in vivo and were partially protected from aging-related bone loss. 
P2ry12–/– macrophages displayed reduced bone resorptive activity 
in response to extracellular ADP. Furthermore, extracellular ADP 
induced RAP1 activation in a P2RY12-dependent manner. Finally, 
genetic or pharmacologic inhibition of P2RY12 partially protect-
ed mice from bone loss associated with arthritis, tumor growth 
in bone, and estrogen loss. These data suggest that antagonism 
of P2RY12 was sufficient to decrease OC function in vivo and 
decrease pathologic bone loss.
Results
P2ry12–/– mice were protected from age-associated bone loss. Under non-
pathologic conditions, young mice (aged 2 months) with germline 
loss of the ADP receptor P2RY12 (P2ry12–/– ) had no significant 
changes in bone mineral density (BMD), trabecular bone volume 
(BV/TV; Supplemental Figure 1, A–C; supplemental material 
available online with this article; doi:10.1172/JCI38576DS1), tra-
becular bone formation rate (BFR) (Supplemental Figure 1, F–H), 
or OC or OB numbers (Supplemental Figure 1, I–M and Supple-
mental Methods) compared with WT littermates. In contrast, 
8-month-old P2ry12–/–  mice showed significantly increased BV/
TV and BMD in the primary and secondary spongiosa of the tibia 
compared with WT littermate controls (Figure 1, A–C). Notably, 
P2ry12–/– mice displayed trabecular bone extending into the diaph-
ysis. Histological analyses of tibiae showed a decreased OC surface 
per bone surface in P2ry12–/– mice, but no detectable change in 
OB number, OB surface per bone surface (Figure 1, I–M), or BFR, 
suggesting that decreased bone resorption predominantly contrib-
uted to the increased bone density in older P2ry12–/– mice.
Bone turnover markers in 2- and 8-month-old mice were evalu-
ated. In 2-month-old mice, both serum carboxy-terminal collagen 
crosslinks (CTX) (a marker of OC resorption) and serum N-ter-
minal propeptide of type I procollagen (P1NP) (a marker of bone 
formation) were significantly decreased in P2ry12–/– mice (Supple-
mental Figure 1, D and E) despite no significant difference in BV/
TV, suggesting that both potential effects of P2RY12 disruption 
on bone resorption and formation were balanced and resulted in 
no significant net change in bone volume. At the 8-month time 
point, serum CTX was significantly decreased in P2ry12–/– (Figure 
1D), while serum P1NP was equivalent to that of WT littermates 
(Figure 1, E–H), consistent with the findings of increased BV/TV 
in P2ry12–/– mice without significant differences in BFR. CTX and 
P1NP levels reflect the bone resorption and formation activities 
happening at a discrete point in time and may reflect transient 
effects of P2RY12 on both OC and on OB, whereas BV/TV by μCT 
demonstrates cumulative effects on total bone, which point to 
defective bone resorption as a predominant consequence of P2ry12 
disruption in 8-month-old mice.
ADP enhanced ex vivo OC bone resorption primarily through the 
P2RY12 receptor. As P2ry12–/– mice exhibited decreased OC activ-
ity in vivo (Figure 1, D and M), cell autonomous P2RY12 expres-
sion and function were evaluated during osteoclastogenesis. 
Expression of P2ry12 increased during ex vivo differentiation 
from BM macrophages (BMMs) (day 0) to Tartrate-resistant acid 
phosphatase–positive (TRAP+) OCs (day 3) and remained higher 
than BMMs in mature multinucleated OCs (day 5) (Figure 2A). 
Immunofluorescence confirmed that WT, but not P2ry12–/–, OC 
cultures expressed P2RY12 (Supplemental Figure 2A). Further-
more, WT cells responded to ADP with a decrease in intracellular 
cAMP (Supplemental Figure 2B), but P2ry12–/– cells or cells treated 
with P2RY12 inhibitor did not respond (Supplemental Figure 2, 
B and C, and Supplemental Methods). Under standard culture 
conditions, without ADP stimulation, P2ry12–/– BMMs differenti-
ated into multinucleated TRAP-positive OCs (Figure 2B), and no 
significant differences compared with WT cells in OC differentia-
tion markers on days 1–5 (Figure 2, C–E, Supplemental Figure 3, 
and Supplemental Methods; all primers are listed in Supplemen-
tal Table 1), macrophage proliferation, or OC apoptosis (data 
not shown) were observed. Functionally, P2ry12–/– cells exhibited 
decreased formation of bone resorption pits compared with WT 
cells (Figure 2, H–J). ADP stimulation resulted in increases in day 3 
OC number and day 6 bone pit area in WT, but not P2ry12–/–, OCs 
(Figure 2, F–J). We performed these experiments using BMMs from 
2- and 8-month-old mice and obtained similar results. Because 
ADP binds both P2Y1 and P2RY12 with high efficiency and poten-
cy, with EC50 values in platelet assays of 1 μM and 60 nM, respec-
tively (9, 44), we determine whether P2Y1 could compensate for 
the loss of P2RY12 expression in OCs. Expression of P2Y1 was not 
different between WT and P2ry12–/– cells and was not significantly 
induced during OC differentiation (Supplemental Figure 4A). In 
both WT and P2ry1–/– cells, ADP stimulation increased actin ring 
and resorption pit formation on bone (Supplemental Figure 4, 
B–G), suggesting that ADP signaling through P2Y1 did not exert a 
significant effect on OC function and that P2RY12 is a major ADP 
receptor in OCs. These results demonstrate that P2ry12–/– cells 
exhibited intact OC differentiation, but decreased resorptive func-
tion, and that extracellular ADP can enhance osteoclastogenesis 
and OC function primarily through P2RY12.
P2ry12–/– OCs showed impaired ADP-mediated actin ring responses 
and RAP1 activation. In platelets, ADP stimulation through the 
P2RY12 receptor acts upstream of the integrin αIIbβ3, result-
ing in platelet adhesion and aggregation (9, 44–46). Because 
OC adhesion via αvβ3 integrin and other integrins is necessary 
for actin ring formation and bone resorption (47), we hypoth-
esized that P2RY12 ligation will act upstream of αvβ3, result-
ing in enhanced OC actin ring formation. ADP enhanced actin 
ring formation on bone in WT, but not P2ry12–/–, cells (Fig-
ure 3, A and B). These results suggest that extracellular ADP 
and P2RY12 signaling can modulate actin ring response to 
extracellular ADP in OCs.
RAP1 GTPase in platelets is activated downstream of P2RY12-
mediated activation of Gβγ and PI3K and is critical for inside-out 
activation of platelet integrin αIIbβ3 (14, 17, 48, 49). RAP1 also 
affects the activation of the related integrin αvβ3 in metastatic 
melanoma cells (50). We found that extracellular ADP resulted 
in a potent induction of activated GTP-bound RAP1 in WT pre-
OCs that was blunted in P2ry12–/– cells (Figure 3, C and D). ADP-
mediated RAP1 activation was intact in integrin β3 gene knockout 
(Itgb3–/–) pre-OCs (Figure 3, C and D), suggesting that P2RY12 is 
upstream of β3 integrin signaling in pre-OCs as it is in platelets. 
The ADP-mediated RAP1 activation in pre-OC was blocked by PI3K 
inhibitors (wortmannin or LY294002), but not by chelation of cal-
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cium or inhibitors of adenylate cyclase or PKA (Figure 3E). Fur-
thermore, the absence of P2RY12 did not result in significant dif-
ferences in the mRNA expression of RAP1 isoforms, RAP1 guanine 
nucleotide exchange factors (GEFs), or GTPase-activating proteins 
(GAPs) during OC differentiation (Supplemental Figure 6). These 
data suggest that the decreased RAP1 activity in P2ry12–/– pre-OCs 
was likely due to lack of signaling via P2RY12 rather than changes 
in the expression of genes encoding RAP1 regulatory factors.
Because M-CSF can induce PI3K activation and can rescue the 
adhesion/spreading defect in β3 integrin–deficient OCs (51) and 
can enhance OC survival (52), we evaluated M-CSF induction of 
RAP1 activation in both P2ry12–/– and β3 integrin–null cells. Treat-
ment of pre-OCs with M-CSF resulted in a rapid and sustained 
increase in RAP1 activation that was similar in WT and Itgb3–/– pre-
OCs, but was delayed in P2ry12–/– cells (Supplemental Figure 5, A 
and B). ADP or M-CSF also activated RAP1 in human OCs gener-
ated from peripheral blood mononuclear cells (data not shown). In 
agreement with ADP treatment (Figure 3, C–E), M-CSF–mediated 
RAP1 activation in pre-OCs was decreased by inhibitors of PI3K, 
but not by inhibitors of adenylate cyclase or PKA or by chelation 
of calcium (Supplemental Figure 5C). These data demonstrate 
that ADP- and M-CSF–mediated RAP1 activation is downstream 
of PI3K and may be mediated in part through P2RY12 signaling 
in OCs. Taken together, these results show that the P2RY12 recep-
tor was an upstream regulator for activation of RAP1 in pre-OCs.
P2ry12–/– mice had decreased arthritis-associated bone loss. Serum 
transfer arthritis (STA) is a well-characterized model of inflam-
matory bone loss that phenocopies the osteolysis associated with 
rheumatoid arthritis (53). In STA, serum from arthritic K/BxN 
mice, which contain high levels of antibodies against the self anti-
gen glucose-6-phosphate isomerase, is injected intraperitoneally 
into naive mice, causing joint-centered inflammation and local 
OC-mediated bone erosion. WT and P2ry12–/– mice exhibited 
similar clinical inflammatory responses, as measured by paw and 
Figure 1
P2ry12–/– mice were protected from age-associated bone loss. (A–C) The primary and secondary spongiosa of the tibias of age- and sex-matched 
WT and P2ry12–/– littermate mice were analyzed by μCT scanning. (A) Representative 3D reconstructions of trabecular bone. Scale bar: 200 μm. 
(B) Calculation of BV/TV and (C) BMD. Tb, trabecular bone. (D and E) Serum concentration of CTX and P1NP measured by ELISA. (F) Bone 
formation was visualized by calcein (first) and alizarin red (second) double-labeling and visualized in the trabecular bone. Scale bars: 200 μm. 
MAR and BFR are shown (G and H). Bone histology, representative TRAP staining (I). Scale bar: 300 μm. (J–M) Quantification of OB and OC 
cells in the primary and secondary spongiosa of the femur. OC number and OC surface per bone surface, OB number and OB surface per bone 
surface are shown. Data represent mean ± SD. n = 6. *P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 2
ADP enhances ex vivo OC bone resorption primarily through the P2RY12 receptor. (A) Quantitative real-time PCR of P2ry12 expression on day 0 
through day 5 of OC differentiation. (B) WT and P2ry12–/– OCs stained for the OC marker protein TRAP on days 3–5 of OC differentiation. Scale bar: 
300 μm. (C–E) Quantitative real-time RT-PCR of OC differentiation markers; nuclear factor of activated T cells, cytoplasmic 1α (Nfatc1α), TRAP, and 
cathepsin K (Ctsk), normalized to levels of gapdh, comparing WT (black bars) and P2ry12–/– (white bars) cells on days 0–5 of OC culture. (F) WT and 
P2ry12–/– macrophages were cultured with 50 ng/ml M-CSF and 50 ng/ml RANKL and treated with or without 1 μM ADP for 3 days. Day 3 OC culture 
was stained for the OC marker protein TRAP. Scale bar: 300 μm. (G) Quantitation of OC number (≥ 3 nuclei). (H) BMMs derived from 8-month-old WT or 
P2ry12–/– mice were cultured with RANKL and MCSF on bone slices for 5 days. ADP was added at a final concentration of 1 μM where indicated. Scale 
bar: 100 μm. (I and J) Quantification of bone pit area. Data represent mean ± SD. n = 3 per condition. *P < 0.05; **P < 0.01.
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ankle swelling (Figure 4, A and B). However, CTX levels indicative 
of bone resorption were significantly decreased in P2ry12–/– mice 
compared with WT (Figure 4C). Histological analysis of ankle 
joints showed no differences in numbers of TRAP+ OC per bone 
surface, but did show significantly decreased OC surface per bone 
surface (Figure 4, D–G) and a decrease in TRAP+ area over total 
tissue area in P2ry12–/– mice. This result mirrors the in vitro find-
ings (Figure 2, F–H) that the P2ry12–/– OCs specifically showed 
decreased function without a significant change in number. Final-
ly, WT mice with STA exhibited a significant decrease in BMD in 
the calcaneal bones as measured by μCT compared with P2ry12–/– 
mice (Figure 4, H and I). These data demonstrate that P2ry12–/– 
mice were partially protected from arthritis-associated bone loss 
despite the development of joint inflammation.
Genetic and pharmacologic inhibition of P2RY12 protected mice from 
tumor-associated bone loss. OC recruitment and activation play a 
critical role in tumor-associated bone loss, pathologic fracture, 
and pain associated with bone metastases (2). Syngeneic osteo-
lytic B16-F10 melanoma cells were inoculated directly into 1 tibia 
and PBS injected into the contralateral tibia of 8-week-old WT and 
P2ry12–/– mice. The tumor burden between WT and P2ry12–/– mice 
was not significantly different as measured by bioluminescence 
imaging (BLI) (Figure 5, A and B); however, μCT showed that WT 
mice displayed significant trabecular bone loss in the tumor-bear-
ing tibiae, whereas P2ry12–/– mice maintained bone volume equiva-
lent to that in the saline-injected tibiae (Figure 5, C and D). His-
tomorphometric evaluation revealed a significant increase in OC 
number and surface in tumor-bearing WT tibiae compared with 
saline-injected tibiae, whereas OC parameters were equivalent in 
both P2ry12–/– bones (Figure 5, E and F), suggesting that P2RY12 
was involved in tumor-induced recruitment of OC.
We next examined the effects of pharmacologic P2RY12 inhi-
bition in a model of bone metastasis. Clopidogrel, a specific 
and irreversible P2RY12 antagonist, is commonly prescribed to 
inhibit platelet aggregation in coronary artery disease, periph-
eral vascular disease, and cerebrovascular disease (11, 54). Bone 
metastases were established using a tumor model of intracar-
diac injection of the syngeneic osteolytic 4T1-GFP-FL murine 
Figure 3
P2ry12–/– OCs showed impaired ADP-induced RAP1 activation. (A and B) BMMs derived from 8-month-old WT or P2ry12–/– mice were cultured 
with RANKL and MCSF on bone slices for 5 days. ADP was added at a final concentration of 1 μM where indicated. (A) Actin ring formation was 
determined by immunofluorescence following Rhodamine-phalloidin staining. Scale bar: 100 μm. Actin ring area was quantitated in B. (C) Western 
blots of total RAP1 and RAP1-GTP in ADP-stimulated pre-OCs (day 3 OC culture). WT and P2ry12–/– pre-OCs were treated with ADP (1 μM) for 
0–15 minutes. Total RAP1 was detected in total cell lysate, while activated RAP1 (RAP1-GTP) was pulled down by using Ral GDS-RBD–labeled 
agarose beads. (D) Densitometry of GTP-RAP1 induction versus WT time 0. (E) WT pre-OCs were treated with or without 1 μM ADP and BAPTA, 
ddADO, H89, or inhibitors of PI3K (wortmannin or LY294002), as indicated. Total RAP1 and activated RAP1 were detected as above. Data rep-
resent mean ± SD and are representative of at least 3 experiments. **P < 0.01.
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mammary carcinoma cell line into immunocompetent BALB/c 
mice. Beginning 2 days after tumor inoculation, clopidogrel 
(30 mg/kg) or vehicle was administered in the drinking water 
for 9 days. We did not observe any change in body weight, fur 
ruffling, general activity, and appearance of mice that were 
treated with clopidogrel. As expected, mice that received clopi-
dogrel had an increased bleeding time. Clopidogrel adminis-
tration did not affect tumor burden (Figure 6, A and B), but 
increased tibial BV/TV and BMD compared with vehicle-treated 
tumor-bearing mice (Figure 6, C and D). While there was no 
significant decrease in OC number, clopidogrel treatment sig-
nificantly reduced the OC surface per trabecular bone surface 
(Figure 6, E–G). Interestingly, clopidogrel treatment was associ-
ated with increased tibial BV/TV and BMD and decreased CTX 
in non–tumor-bearing 6-week-old WT mice (Supplemental Fig-
ure 7, A–D). Together, these results demonstrate that P2ry12–/– 
mice and clopidogrel-treated WT mice were protected from 
tumor-induced osteolysis through effects on OCs.
P2RY12 antagonism partially protected mice from ovariectomy-induced 
bone loss. Because P2ry12–/– mice were partially protected from age-
associated bone loss (Figure 1), we evaluated whether the absence 
of P2RY12 could prevent bone loss in a model of estrogen deficien-
cy–induced osteoporosis. Ovariectomy (OVX) was performed on 
P2ry12–/– and WT littermates at 14 weeks, an age at which no signif-
icant differences in baseline BV/TV were observed. At 2 and 5 weeks 
after OVX, P2ry12–/– mice had lost significantly less tibial bone 
mass than WT controls (Figure 7A). Serum CTX was significantly 
lower in P2ry12–/– mice after OVX, whereas serum P1NP (Figure 
7B) and BFR (Figure 7, C and D) were not significantly changed. In 
agreement, histomorphometric analysis showed that the number 
Figure 4
P2ry12–/– mice had decreased arthritis-associ-
ated bone loss. STA was induced in 6-week-old 
WT (n = 8) or P2ry12–/– (n = 6) mice by injec-
tion of K/BxN serum on days 0 and 2. (A) Hind 
paw thickness was measured bilaterally daily. 
(B) Inflammation area over total ankle area was 
determined by measuring inflammatory tissue 
area on hematoxylin staining of ankle tissue. 
(C) Serum CTX assay to measure OC activity 
on day 11. n = 5 per group. (D–F) Histological 
analyses of ankle with TRAP staining. Scale 
bar: 100 μm. Scale bar: 100 μm. Quantitation 
of TRAP+ area (E), OC number (N.) per bone 
surface (F), and OC surface per bone surface 
(G) in the boxed ROI. (H and I) Representative 
μCT 3D reconstructions of hind limb ankle joints 
11 days following STA induction and calcaneal 
bone BMD are shown. Scale bar: 300 μm. Data 
represent mean ± SD. *P < 0.05; **P < 0.01.
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and surface area of OCs were significantly higher in the femoral 
bones of WT mice compared with P2ry12–/– mice, whereas OB num-
ber and surface area were not significantly different between WT 
and P2ry12–/– mice following OVX (Figure 7, E and F). BMD did 
decline in P2ry12–/– mice after OVX by day 35, but to a lesser extent 
than in WT mice. Together, these data suggest that P2ry12–/– mice 
were partially protected from OVX-induced bone loss.
Likewise, pharmacologic inhibition of P2RY12 with clopi-
drogel (orally administered at 30 mg/kg/d) protected WT mice 
from significant OVX-induced bone loss at day 14 compared 
with sham surgery control (Figure 8A). At day 35, all OVX mice 
experienced significant bone loss compared with sham controls; 
however, clopidogrel-treated mice remained partially protected 
from OVX-mediated bone loss compared with vehicle controls 
(Figure 8B). At day 14, serum CTX and P1NP levels were elevated 
in both OVX groups compared with sham groups, indicative of 
increased bone turnover (Figure 8C); however, clopidogrel treat-
ment significantly decreased CTX levels compared with vehicle, 
demonstrating that P2RY12 antagonism blunted osteoclastic 
bone resorption. While the overall extent of bone turnover was 
decreased by day 35 after OVX, serum CTX levels remained sig-
nificantly higher in vehicle-treated mice that had undergone OVX 
compared with sham-treated mice, while clopidogrel treatment 
decreased the CTX levels of OVX mice to a point equivalent to 
that of the sham control group (Figure 8C). Serum P1NP levels 
showed no significant difference between groups at day 35 (Fig-
ure 8C). Clopidogrel treatment blunted the increase in OC num-
ber and OC surface per bone surface observed in vehicle-treated 
mice following OVX at day 14 and day 35 (Supplemental Figure 
8, A and B, and Figure 8, D and E). OB number and surface per 
bone surface were not significantly different between clopidogrel 
and vehicle treatment (Supplemental Figure 8, A and B). Likewise, 
although OVX itself did cause a decrease in BFR at day 14, but 
not day 35, P2RY12 antagonism with clopidogrel did not alter 
this response compared with vehicle (Supplemental Figure 8, 
C–F). In agreement with results obtained with genetic disruption 
of P2ry12, these data demonstrate that pharmacologic blockade 
of P2RY12 partially protected mice from OVX-induced bone loss 
and that the protection was predominantly from a blunting of 
OC-mediated resorption.
Discussion
In this report, we demonstrate what we believe is a novel role for 
the ADP receptor P2RY12 in the function of bone-resorbing OCs, 
particularly in preclinical models of pathologic bone loss associ-
ated with postmenopausal osteoporosis, rheumatoid arthritis, 
Figure 5
Genetic inhibition of P2RY12 protected mice from tumor-associated bone loss. (A and B) 1 × 104 B16-FL tumor cells (right leg) or PBS (control, 
left leg) were injected directly into the tibia (n = 6 per group). (A and B) The tumor burden in hind limbs was measured by BLI. (C and D) BV/TV 
and BMD in the primary and secondary spongiosa of PBS-injected or tumor-bearing tibia were analyzed by μCT. (E) TRAP-stained tibial sections 
(×4) of WT (top) and P2ry12–/– mice (bottom) 10 days after tumor injection. T, tumor; M, marrow. TRAP+ staining (dark red areas) indicates OC 
presence. Scale bar: 300 μm. (F) OC number and surface per bone surface in the primary and secondary spongiosa of the tibia are shown in 
saline-injected tibia (S) (black bars) and tumor-injected tibia (T) (white bars). Data represent mean ± SD. n = 6. *P < 0.05.
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and bone metastases. We demonstrate that antagonism with the 
FDA-approved P2RY12 inhibitor, clopidogrel, decreased bone loss 
in murine models of osteoporosis and tumor-associated bone loss. 
These data suggest that clopidogrel or novel ADP and P2RY12-
targeted therapies could be clinically evaluated in disease states 
characterized by excessive bone resorption.
The phenotypic overlap between P2ry12–/– and Itgb3–/– mice is 
striking. Itgb3–/– mice have a severe platelet aggregation defect and 
have increased bone mass with decreased OC function (25, 47, 55). 
P2ry12–/– mice display similar defects in platelet aggregation (10) 
and osteoclastic bone resorption, albeit both are milder than those 
of the Itgb3–/– mice. Similarly to Itgb3–/–, P2ry12–/– mice also devel-
oped increased trabecular bone mass with aging due to impaired 
OC function and demonstrated protection from tumor-induced 
bone loss, again less severe than in the Itgb3–/– mice (22, 47). These 
results suggest that P2RY12 and β3 integrin may lie in the same 
signaling pathway necessary for OC formation and function, as 
they do for platelet adhesion.
Decreased adhesion, actin ring formation, migration, and 
resorption of Itgb3–/– OCs have been reported (23). Adhesion is 
critical to the formation of actin rings in OCs and the sealing zone 
necessary for directional delivery of bone-resorbing enzymes and 
acids (1, 47, 56). Because P2RY12 has previously been shown to 
play a role in adhesion in platelets and microglial cells (10, 29) and 
is required for microglial migration toward ADP (26, 31, 57), we 
evaluated its role in actin ring responses. Accordingly, we report 
a decrease in ADP-enhanced actin ring formation on bone by 
P2ry12–/– cells. We hypothesized that P2RY12 acts upstream of β3 
integrin through a GTPase-related mechanism in OCs similar to 
that in platelets and that RAP1 GTPase plays an important role in 
this signaling pathway. In addition to its typical Gαi-coupled roles, 
P2RY12 is known to couple to the Gβγ portion of the G protein 
heterotrimer that activates PI3K, Akt, and eventually RAP1, lead-
ing to integrin activation in platelets (12–15, 17, 58–62). We found 
that RAP1 activation was downstream of P2RY12 in pre-OCs and 
that this activation was ADP dependent.
Interestingly, β3 integrin–null OCs had intact ADP-induced 
RAP1 activation, suggesting that β3 integrins are downstream of 
P2RY12 signaling. P2Y1, another Gαq-coupled ADP receptor, is also 
expressed by OC lineage cells; however, our data that responses to 
ADP were impaired in P2ry12–/– but not P2ry1–/– cells suggest that 
P2RY12 is necessary for the majority of ADP-dependent RAP1 activ-
ity in OC. We cannot rule out that P2Y1 may cooperate with P2RY12 
during osteoclastogenesis in situations associated with increased 
Figure 6
Pharmacologic inhibition of P2RY12 protected mice from tumor-associated bone loss. 4T1-GFP-FL tumor cells were directly injected into the left 
cardiac ventricle of WT Balb/c mice (n = 12 per group). Clopidogrel treatment (30 mg/kg/d in drinking water) was begun 2 days after tumor cell 
injection and continued for 9 days. (A) The tumor burden in hind limbs measured by BLI and (B) representative pictures of BLI at day 11. (C and 
D) BV/TV and BMD of the tibia of tumor-bearing mice at day 11 were analyzed by μCT. (E) TRAP-stained hind limb sections at day 11 after tumor 
injection and vehicle or clopidogrel treatment. TRAP+ staining (dark red areas) indicates OC presence. Scale bar: 300 μm. OC number and surface 
in the primary and secondary spongiosa of the tibia are shown (F and G). Data represent mean ± SD. *P < 0.05; **P < 0.01.
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extracellular ATP/ADP. Likewise, RAP1 activation can also modu-
late outside-in integrin signaling, which is critical to OC function 
(12, 24, 63). Taken together, our data suggest that ADP-mediated 
RAP1 activation occurs in OC and is largely dependent on P2RY12.
In addition to RAP1, P2RY12 may also be upstream of other 
GTPases, such as Rac or Cdc42, which are also critical to OC func-
tion (63, 64). The potentially varying role of different purinergic 
receptors and RAP1 in OCs is currently under investigation. We 
Figure 7
P2ry12–/– mice were partially protected from OVX-induced bone loss. OVX was performed on 14-week-old P2ry12–/– and WT littermates (n = 5 
per group). (A) BV/TV and BMD were measured in the primary and secondary spongiosa of the tibia of live animals viva CT scanning prior to 
and at days 14 and 35 following OVX. (B) Serum concentration of CTX and P1NP measured by ELISA. (C) Bone formation was visualized by 
calcein (first) and alizarin red (second) double-labeling and visualized in the trabecular bone. Representative photographs: original magnifica-
tion, ×2.5, scale bar: 300 μm; original magnification, ×20, scale bar: 50 μm. (D) MAR and BFR were measured. (E) TRAP-stained hind limb sec-
tions after OVX. Scale bar: 300 μm. (F) Quantification of OC and OB cells in the primary and secondary spongiosa of the femur. Data represent 
mean ± SD. n = 5. *P < 0.05.
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P2ry12–/– mice may be attributed to low extracellular ADP/ATP 
concentrations present under these conditions. In contrast, the 
increased amounts of bone remodeling and tissue repair associ-
ated with aging skeletons and organs likely release ATP, resulting 
in increased P2RY12 signaling, similar to that occurring in the 
presence of tumor or inflammatory stimuli. Under such condi-
tions of aging (8-month-old mice) or pathology, we found that 
the genetic absence or pharmacological inhibition of P2RY12 
blunted OC function, resulting in a preservation of bone mass. 
Interestingly, the administration of clopidogrel to non–tumor-
bearing 6-week-old mice, a time at which bone turnover (and thus, 
likely extracellular ATP/ADP) is high due to skeletal growth, also 
increased bone volume. However, drug administration to 16-week-
old mice (sham surgery group in Figure 8), a time when peak bone 
mass has already been mostly reached and thus turnover and ATP 
release would be expected to be decreased, did not affect bone 
mass. In experiments using both genetic and pharmacologic dis-
ruption of P2RY12, we observed the most protection from bone 
loss after OVX occurred within the first 2 weeks. We hypothesize 
that extracellular ADP levels are likely higher in the early time 
points after OVX, but it is also possible that P2RY12 disruption 
cannot conclude that the activation of P2RY12 yields activation 
of only β3-containing integrins, since RAP1 activity is upstream of 
many integrin heterodimers (12, 14, 20, 49). We propose that acti-
vation of specific integrins by P2RY12 and other purinergic recep-
tors may exist at different phases of OC formation, such as fusion 
and migration; this hypothesis will be tested in future studies.
Our studies demonstrated that P2RY12 exerts its most 
prominent effects on bone during pathological situations in 
which extracellular ATP would be increased due to ongoing tis-
sue damage and repair. Extracellular ATP can be degraded into 
ADP by extracellular dephosphorylating enzymes; therefore, 
the extracellular ADP concentration is positively corelated with 
extracellular ATP levels. Tumor cells are known to establish a 
microenvironment containing more than 100 μM extracellular 
ATP, whereas ATP concentration is undetectable in healthy tis-
sues (36). Likewise, the ATP concentration in synovial fluid from 
patients with rheumatoid arthritis is substantially elevated at 
50 nM, but undetectable in normal joint fluids (43). Thus, under 
normal physiologic conditions, there is a minimal concentra-
tion of extracellular ATP in tissues and blood. Thus, the minimal 
effects on in vivo bone mass observed in healthy 2-month-old 
Figure 8
P2RY12 antagonism partially protected mice from OVX-induced bone loss. 14-week-old WT C57BL/6 mice underwent OVX (n = 8) or 
sham operation (sham) (n = 10) and were treated with clopidogrel (30 mg/kg/day) or vehicle-control in drinking water for 2 or 5 weeks. 
Tibias from sham-operated and OVX mice were examined by μCT. (A and B) BV/TV in the primary and secondary spongiosa of the tibia 
after OVX. (C) Serum concentration of CTX and P1NP measured by ELISA. (D) TRAP-stained hind limb sections after OVX. Scale bar: 
300 μm. (E) Quantification of OC and OB cells 35 days after OVX. OC number (N.OC) per bone surface (N.OC/BS) and OB number per 
bone surface (N.OB/BS) in the primary and secondary spongiosa of the femur. Data represent mean ± SD. n = 5. *P < 0.05; **P < 0.01; 
***P < 0.001; ****P < 0.0001.
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bone mass (71). We have previously reported that mice with con-
ditionally deleted β3 integrin in platelets had normal bone mass 
despite severe platelet aggregation defects; conversely, mice with 
conditional deletion of β3 integrin in myeloid/OC lineage cells had 
osteosclerosis and increased bone mass despite normal platelet 
function (72), suggesting that defective platelet function does not 
necessarily modulate bone mass.
Currently, there are no prospective clinical data on BMD in 
patients using clopidogrel. Interestingly, a population-based epi-
demiological study reported that the use of platelet inhibitors 
aspirin and dipyridamole was associated with increased risk of 
osteoporotic fractures, but this association was not observed with 
clopidogrel (73). Clinical studies evaluating the effects on bone in 
patients receiving clopidogrel or trials of clopidogrel in patients 
with excessive bone resorption are warranted to determine wheth-
er clopidogrel or other novel ADP and P2RY12-targeted thera-
pies (11, 67, 74) could have a role as in the treatment of disease 
states characterized by excessive bone resorption. We propose that 
P2RY12 targeting would likely only have effects on bone during 
localized increases in extracellular ADP that can occur during tis-
sue damage, inflammation, and cancer, with little effects on nor-
mal systemic bone turnover. Our data suggest that antagonism of 
the ADP receptor, P2RY12, using currently available drugs could 
represent a new approach to preventing pathologic bone loss.
Methods
Mice. WT, P2ry12–/– (10), and Itgb3–/– mice (75) on a pure C57BL/6 
background were housed under pathogen-free conditions according to 
the guidelines of the Division of Comparative Medicine, Washington 
University School of Medicine. Unless noted, all mice were used at 6 to 
10 weeks of age. P2ry1–/– BM cells (BMCs) were provided by Christian 
Gachet (Université de Strasbourg, Strasbourg, France) (76).
Micro-computed tomography. Tibial metaphyses were scanned by micro-
computed tomography (μCT) (μCT-40; Scanco Medical). The trabecular 
region from forty 2D slices (0.8 mm) in the primary and secondary spon-
giosa of the tibia was selected using contours inside the cortical shell on 
each 2D image, with the growth plate as a marker to determine a consistent 
location to start analysis. A 3D cubical voxel model of bone was built, and 
calculations were made for BV/TV and apparent BMD (calibrated against 
a hydroxyapatite phantom). A threshold of 300 (out of 1,000) was used to 
differentiate trabecular bone from nonbone.
Serum CTX and P1NP assays. CTX and P1NP were measured in fasting 
serum using ELISA systems (Immunodiagnostic Systems Inc.).
OC culture assay. To generate primary BMMs, whole BM was extracted 
from the femurs and tibias of mice and plated in petri dishes in α-MEM 
medium containing 10% fetal bovine serum and M-CSF–containing CMG-
14-12 cell culture supernatant (50 ng/ml). For OC differentiation assays, 
BMMs were plated at 2 × 104 per well in 48-well cell culture plates and fed 
daily with osteoclastogeneic medium (α-MEM containing 10% FBS, CMG-
14-12 supernatant [50 ng/ml], and GST-RANKL [50 ng/ml]) for 3 to 6 days, 
as previously described (77). Then, 1 μM ADP (Sigma-Aldrich) was added 
daily to cultures as indicated. TRAP staining was performed according to 
the manufacturer’s instructions (Sigma-Aldrich). The number of TRAP+ 
OCs with 3 or more nuclei were counted using ImageJ software (NCBI).
In vitro bone resorption assay. Bone resorption assays were performed 
as previously described (77). For actin ring staining, cells were cultured 
on bovine bone slices in osteoclastogeneic medium with or without 
1 μm ADP for 6 days. Cells were fixed in 4% paraformaldehyde, permea-
bilized in 0.1% Triton X-100, rinsed in PBS, and immunostained with 
Alexa Fluor 488 phalloidin (Molecule Probes) or Rhodamine-phalloidin 
could cause small sequential decreases in OB formation in the 
later time points. Therefore, the clinical benefit of P2RY12 inhibi-
tion or antagonism may be strongest during the early/peak time 
period after injury or pathology.
The dosage of clopidogrel used in the in vivo studies was 30 
mg/kg/d, which, after species conversion, is higher than the stan-
dard 75 mg/d dosage used in humans. However, except for the 
expected longer bleeding time, we did not observe any negative 
effects on general health, such as weight, grooming behavior, and 
activity level. There could be indirect effects on bone of high-dose 
clopidogrel from effects on platelets and perhaps off-target effects. 
Thus, it is possible that some of the bone effects from clopidogrel 
may not be present or may be different at lower doses, and this will 
be explored in future studies.
In the disease models examined here, the effects of P2RY12 on 
osteolysis and bone resorption predominated, and P2RY12 genetic 
deletion or pharmacological inhibition consistently yielded a net 
increase in bone mass. However, we cannot rule out that P2RY12 
may have subtle effects on bone formation and OB function. In 
aging mice, we did not detect differences in OB number per bone 
surface in P2ry12–/– and WT mice, but there probably was an abso-
lute increase in OB number, given the higher BV/TV in P2ry12–/– 
mice. Thus, the function of individual OBs could be decreased, but 
this could have been balanced by the increased number to give a 
constant P1NP. Notably, we did observe modest decreases in serum 
markers of both bone formation and resorption in 2-month-old 
P2ry12–/– mice, although there were no changes in BMD or BFR 
in these young mice. This could be consistent with balanced and 
coupled bone formation and resorption that would have no net 
effect on bone volume. It is also possible that P2RY12 exerts a 
transient effect on OB function that may be reflected by serum 
P1NP at a single, discrete time point, but did not result in a mea-
surable change in the cumulative BFR measured over a period of 
5 days. Such transient versus cumulative measurements of OB 
activity may also account for the observation of increased P1NP, yet 
decreased BFR, observed 2 weeks following OVX (Figure 8 and Sup-
plemental Figure 8). A detailed analysis of the vertebral and femo-
ral bones throughout the life span of P2ry12–/– mice will be impor-
tant. Taken together, it is possible that P2RY12 may decrease OB 
function, but in the in vivo models that we evaluated, the OC dys-
function predominated, resulting in an overall increase in BV/TV. 
The role of P2RY12 in OBs is under intense study.
It has been reported that purinergic signaling can modulate 
platelet function, inflammation, and pathologic angiogenesis, 
which could modulate bone cell function in certain disease states 
(2, 22, 36, 65–68). Recent preclinical data is conflicting regarding 
the role of clopidogrel in inflammation both dependently and 
independently of its effects on platelets (36, 68). We found that 
in the STA model, the amount of clinical inflammation as mea-
sured by paw swelling was similar between WT and P2ry12–/– mice. 
However, we cannot rule out that differences in specific inflam-
matory cytokines did not exist between genotypes, causing effects 
on pathologic osteolysis. Interestingly, β3 integrins play a critical 
role in platelet function, OC function, inflammatory responses, 
and pathologic angiogenesis (69, 70). It is possible that some of 
the bone resorption effects in the disease models evaluated in our 
P2RY12 studies could in part be due to non–cell-autonomous 
effects of P2RY12 signaling on neoangiogenesis, platelet activa-
tion, and/or inflammation. It has been reported that platelet 
defects in a mouse model of von Willebrand disease had increased 
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tumor cell injection. Mice underwent blinded necropsy on day 11 after 
tumor cell injection, and tibias were fixed and analyzed by μCT. Mice 
were discarded from the final analysis when the animal died before day 
11 or necropsy showed a large mediastinal tumor indicative of injection 
of tumor cells into the chest cavity. In order to have sufficient remaining 
trabecular bone for histomorphometry analysis, all data were analyzed 
from the tibia where areas of non–tumor-invaded bone were still pres-
ent, since tumor burden is often higher in femurs, likely due to increased 
marrow space.
BLI. For BLI of live animals, previously described mice were injected 
intraperitoneally with 150 μg/g D-luciferin (Biosynth) in PBS, anesthe-
tized with 2.5% isoflurane, and imaged with a charge-coupled device 
(CCD) camera-based BLI system (IVIS 100; Caliper; exposure time 1–60 
seconds, binning 8, field of view 12, f/stop 1, open filter, anterior side). 
Signal was displayed as photons/s/cm2/sr (79). Regions of interest (ROI) 
were defined manually around the legs using Living Image and IgorPro 
Software (Version 2.50).
OVX. OVX or sham surgeries were performed as described in ref. 80 
with the following modifications: 14-week-old female C57BL/6 mice or 
P2ry12–/– mice were anesthetized using 2% isoflurane; ovaries were exposed 
through an abdominal approach and removed by cauterization. The peri-
toneum and skin were sutured separately. Pain was managed by subcutane-
ous injection of 0.075 mg/kg bupernorphine followed by 1:30 dilution of 
children’s liquid pain reliever (32 mg acetaminophen/ml) in the drinking 
water for 2 days. Clopidogrel treatment (30 mg/kg/d in drinking water) 
was begun 2 days after OVX.
Statistics. Data are shown as mean ± SD unless noted otherwise. All exper-
iments were analyzed using 2-tailed unpaired Student’s t test for 2 groups 
or 1-way ANOVA with Bonferroni’s post-hoc test for 3 or more groups by 
Prism (GraphPad Software). P < 0.05 was considered significant.
Study approval. The study protocols were approved by the Washington 
University Animal Studies Committee.
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(Invitrogen). To quantify resorption lacunae, cells were removed from 
bone slices, and bone slices were incubated with peroxidase-conjugat-
ed wheat germ agglutinin (WGA) (Sigma-Aldrich) and stained with 
3,3′-diaminobenzidine (Sigma-Aldrich). Resorption area was determined 
from five 4× fields using BioquantOsteo software (Bioquant) by an oper-
ator blinded to genotype.
RAP1 pull down assays and Western blotting. BMMs derived from 2-month-
old mice and OCs were cultured as above; day 3 OCs (pre-OCs) were used 
for experiments. After ADP (0–1 μm) or CMG-14-12 supernatant (100 
ng/ml) treatment, cells were washed in PBS and harvested into Tris Lysis 
Buffer (TLB) (50 mM Tris-HCl, pH 7.4, 500 mM NaCl, 1% NP40, 2.5 mM 
MgCl2, and 10% glycerol) plus 1% Mammalian Protease Inhibitor Cocktail 
(Sigma-Aldrich). As indicated, cells were also treated with PI3K inhibitor 
(wortmannin or LY294002), inhibitor for adenylate cyclase (ddADO), or 
PKA (H89), or by chelation of calcium (BAPTA). A sample of the superna-
tant was incubated with Ral GDS-RBD–labeled Agarose Beads (Upstate 
Biotechnology) for 45 minutes at 4°C. After washing, bound RAP1-GTP 
was released from the beads by boiling in 2× Laemmli reducing sample 
buffer. Western blotting was used to detect total RAP1 and RAP1-GTP 
using rabbit anti-RAP1a/1b antibody (Cell Signaling Technology Inc.), 
secondary HRP-conjugated goat anti-rabbit IgG (Calbiochem), and 
chemiluminescent substrates for HRP (SuperSignal; Thermo Scientific). 
Densitometry, where appropriate, was performed using Quantity One 
software ver. 4.5.1 (Bio-Rad).
STA. The STA model was described previously (53). Briefly, 6-week-old 
WT and P2ry12–/– mice were used in this model; arthritis was induced by 
injection of serum from arthritic K/BxN mice on days 0 and 2, and hind 
paw thickness was measured bilaterally every day (n = 5 per group). On 
day 11, hind limbs were fixed and scanned by μCT. Histologic sections of 
the hind paw were also analyzed as in Bone histomorphometry. Inflammation 
area over total ankle area was determined by measuring inflammatory tis-
sue area on H&E staining of ankle tissue. TRAP+ area over total tissue area, 
OC number, and OC surface per bone surface were measured by Bioquant 
Osteo software (Bioquant Image Analysis Corp.) on TRAP-stained slices 
of ankle tissue.
Image acquisition. Images of cells and isolated tibial, femoral, and calcane-
al bones were taken with a Nikon Eclipse TE300 inverted microscope con-
nected to a Magnafire camera model S99802 (Optronics). The ×4 Nikon 
lens with numerical aperture 0.13, the ×10 Nikon lens with numerical aper-
ture 0.30, or the ×40 Nikon lens with numerical aperture 0.60 was used.
Bone histomorphometry. Mouse hind limbs or tibias/femurs were fixed in 
10% formalin for 24 hours and decalcified in 14% EDTA solution for 2 
weeks (tibia and femur) or 3 weeks (hind limbs with soft tissue). Paraffin-
embedded sections were stained with H&E for OB parameter analysis or 
stained with TRAP for OC parameter analysis within the primary and sec-
ondary spongiosa. Sections were analyzed by a blinded operator according 
to a standard protocol using Bioquant Osteo V7 10.10 (Bioquant Image 
Analysis Corp.).
Tumor and bone metastasis models. The B16-F10 C57BL/6 murine melano-
ma cell line (ATCC) was modified to express firefly luciferase (B16-FL) as 
described (77). For intratibial injections, 1 × 104 B16-FL cells in 50 μl PBS 
were injected into the right tibia, and PBS (50 μl) was injected into the left 
tibia as an internal control (77). At day 9, tibias were fixed and decalcified 
for histologic sections.
For intracardiac injections, the left ventricular chambers of 6-week-
old female Balb/c mice were inoculated with 105 4T1 BALB/c triple-
negative murine breast cancer cells labeled with GFP-firefly luciferase 
gene (4T1-GFP-FL) (78) in 50 μl PBS as previously described (77). BLI 
was performed on days 2, 7, 9, and 11 after inoculation. Treatment with 
clopidogrel (30 mg/kg/d in drinking water) was begun 2 days after 
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